Cargando…
An innovative approach to induce cross-protective immunity against porcine reproductive and respiratory syndrome virus in the lungs of pigs through adjuvanted nanotechnology-based vaccination
Porcine reproductive and respiratory syndrome (PRRS) is an economically devastating respiratory disease of pigs. The disease is caused by the PRRS virus (PRRSV), an Arterivirus which is a highly mutating RNA virus. Widely used modified live PRRSV vaccines have failed to prevent PRRS outbreaks and re...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969340/ https://www.ncbi.nlm.nih.gov/pubmed/24711701 http://dx.doi.org/10.2147/IJN.S59924 |
_version_ | 1782309258567614464 |
---|---|
author | Binjawadagi, Basavaraj Dwivedi, Varun Manickam, Cordelia Ouyang, Kang Torrelles, Jordi B Renukaradhya, Gourapura J |
author_facet | Binjawadagi, Basavaraj Dwivedi, Varun Manickam, Cordelia Ouyang, Kang Torrelles, Jordi B Renukaradhya, Gourapura J |
author_sort | Binjawadagi, Basavaraj |
collection | PubMed |
description | Porcine reproductive and respiratory syndrome (PRRS) is an economically devastating respiratory disease of pigs. The disease is caused by the PRRS virus (PRRSV), an Arterivirus which is a highly mutating RNA virus. Widely used modified live PRRSV vaccines have failed to prevent PRRS outbreaks and reinfections; moreover, safety of the live virus vaccines is questionable. Though poorly immunogenic, inactivated PRRSV vaccine is safe. The PRRSV infects primarily the lung macrophages. Therefore, we attempted to strengthen the immunogenicity of inactivated/killed PRRSV vaccine antigens (KAg), especially in the pig respiratory system, through: 1) entrapping the KAg in biodegradable poly(lactic-co-glycolic acid) nanoparticles (NP-KAg); 2) coupling the NP-KAg with a potent mucosal adjuvant, whole cell lysate of Mycobacterium tuberculosis (M. tb WCL); and 3) delivering the vaccine formulation twice intranasally to growing pigs. We have previously shown that a single dose of NP-KAg partially cleared the challenged heterologous PRRSV. Recently, we reported that NP-KAg coupled with unentrapped M. tb WCL significantly cleared the viremia of challenged heterologous PRRSV. Since PRRSV is primarily a lung disease, our goal in this study was to investigate lung viral load and various immune correlates of protection at the lung mucosal surfaces and its parenchyma in vaccinated heterologous PRRSV-challenged pigs. Our results indicated that out of five different vaccine-adjuvant formulations, the combination of NP-KAg and unentrapped M. tb WCL significantly cleared detectable replicating infective PRRSV with a tenfold reduction in viral RNA load in the lungs, associated with substantially reduced gross and microscopic lung pathology. Immunologically, strong humoral (enhanced virus neutralization titers by high avidity antibodies) and cell-mediated immune responses (augmented population of interferon-γ secreting CD4(+) and CD8(+) lymphocytes and reduced secretion of immunosuppressive cytokines) in the lungs were observed. In conclusion, combination of NP-KAg and soluble M. tb WCL elicits broadly cross-protective anti-PRRSV immunity in the pig respiratory system. |
format | Online Article Text |
id | pubmed-3969340 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-39693402014-04-07 An innovative approach to induce cross-protective immunity against porcine reproductive and respiratory syndrome virus in the lungs of pigs through adjuvanted nanotechnology-based vaccination Binjawadagi, Basavaraj Dwivedi, Varun Manickam, Cordelia Ouyang, Kang Torrelles, Jordi B Renukaradhya, Gourapura J Int J Nanomedicine Original Research Porcine reproductive and respiratory syndrome (PRRS) is an economically devastating respiratory disease of pigs. The disease is caused by the PRRS virus (PRRSV), an Arterivirus which is a highly mutating RNA virus. Widely used modified live PRRSV vaccines have failed to prevent PRRS outbreaks and reinfections; moreover, safety of the live virus vaccines is questionable. Though poorly immunogenic, inactivated PRRSV vaccine is safe. The PRRSV infects primarily the lung macrophages. Therefore, we attempted to strengthen the immunogenicity of inactivated/killed PRRSV vaccine antigens (KAg), especially in the pig respiratory system, through: 1) entrapping the KAg in biodegradable poly(lactic-co-glycolic acid) nanoparticles (NP-KAg); 2) coupling the NP-KAg with a potent mucosal adjuvant, whole cell lysate of Mycobacterium tuberculosis (M. tb WCL); and 3) delivering the vaccine formulation twice intranasally to growing pigs. We have previously shown that a single dose of NP-KAg partially cleared the challenged heterologous PRRSV. Recently, we reported that NP-KAg coupled with unentrapped M. tb WCL significantly cleared the viremia of challenged heterologous PRRSV. Since PRRSV is primarily a lung disease, our goal in this study was to investigate lung viral load and various immune correlates of protection at the lung mucosal surfaces and its parenchyma in vaccinated heterologous PRRSV-challenged pigs. Our results indicated that out of five different vaccine-adjuvant formulations, the combination of NP-KAg and unentrapped M. tb WCL significantly cleared detectable replicating infective PRRSV with a tenfold reduction in viral RNA load in the lungs, associated with substantially reduced gross and microscopic lung pathology. Immunologically, strong humoral (enhanced virus neutralization titers by high avidity antibodies) and cell-mediated immune responses (augmented population of interferon-γ secreting CD4(+) and CD8(+) lymphocytes and reduced secretion of immunosuppressive cytokines) in the lungs were observed. In conclusion, combination of NP-KAg and soluble M. tb WCL elicits broadly cross-protective anti-PRRSV immunity in the pig respiratory system. Dove Medical Press 2014-03-24 /pmc/articles/PMC3969340/ /pubmed/24711701 http://dx.doi.org/10.2147/IJN.S59924 Text en © 2014 Binjawadagi et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Binjawadagi, Basavaraj Dwivedi, Varun Manickam, Cordelia Ouyang, Kang Torrelles, Jordi B Renukaradhya, Gourapura J An innovative approach to induce cross-protective immunity against porcine reproductive and respiratory syndrome virus in the lungs of pigs through adjuvanted nanotechnology-based vaccination |
title | An innovative approach to induce cross-protective immunity against porcine reproductive and respiratory syndrome virus in the lungs of pigs through adjuvanted nanotechnology-based vaccination |
title_full | An innovative approach to induce cross-protective immunity against porcine reproductive and respiratory syndrome virus in the lungs of pigs through adjuvanted nanotechnology-based vaccination |
title_fullStr | An innovative approach to induce cross-protective immunity against porcine reproductive and respiratory syndrome virus in the lungs of pigs through adjuvanted nanotechnology-based vaccination |
title_full_unstemmed | An innovative approach to induce cross-protective immunity against porcine reproductive and respiratory syndrome virus in the lungs of pigs through adjuvanted nanotechnology-based vaccination |
title_short | An innovative approach to induce cross-protective immunity against porcine reproductive and respiratory syndrome virus in the lungs of pigs through adjuvanted nanotechnology-based vaccination |
title_sort | innovative approach to induce cross-protective immunity against porcine reproductive and respiratory syndrome virus in the lungs of pigs through adjuvanted nanotechnology-based vaccination |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969340/ https://www.ncbi.nlm.nih.gov/pubmed/24711701 http://dx.doi.org/10.2147/IJN.S59924 |
work_keys_str_mv | AT binjawadagibasavaraj aninnovativeapproachtoinducecrossprotectiveimmunityagainstporcinereproductiveandrespiratorysyndromevirusinthelungsofpigsthroughadjuvantednanotechnologybasedvaccination AT dwivedivarun aninnovativeapproachtoinducecrossprotectiveimmunityagainstporcinereproductiveandrespiratorysyndromevirusinthelungsofpigsthroughadjuvantednanotechnologybasedvaccination AT manickamcordelia aninnovativeapproachtoinducecrossprotectiveimmunityagainstporcinereproductiveandrespiratorysyndromevirusinthelungsofpigsthroughadjuvantednanotechnologybasedvaccination AT ouyangkang aninnovativeapproachtoinducecrossprotectiveimmunityagainstporcinereproductiveandrespiratorysyndromevirusinthelungsofpigsthroughadjuvantednanotechnologybasedvaccination AT torrellesjordib aninnovativeapproachtoinducecrossprotectiveimmunityagainstporcinereproductiveandrespiratorysyndromevirusinthelungsofpigsthroughadjuvantednanotechnologybasedvaccination AT renukaradhyagourapuraj aninnovativeapproachtoinducecrossprotectiveimmunityagainstporcinereproductiveandrespiratorysyndromevirusinthelungsofpigsthroughadjuvantednanotechnologybasedvaccination AT binjawadagibasavaraj innovativeapproachtoinducecrossprotectiveimmunityagainstporcinereproductiveandrespiratorysyndromevirusinthelungsofpigsthroughadjuvantednanotechnologybasedvaccination AT dwivedivarun innovativeapproachtoinducecrossprotectiveimmunityagainstporcinereproductiveandrespiratorysyndromevirusinthelungsofpigsthroughadjuvantednanotechnologybasedvaccination AT manickamcordelia innovativeapproachtoinducecrossprotectiveimmunityagainstporcinereproductiveandrespiratorysyndromevirusinthelungsofpigsthroughadjuvantednanotechnologybasedvaccination AT ouyangkang innovativeapproachtoinducecrossprotectiveimmunityagainstporcinereproductiveandrespiratorysyndromevirusinthelungsofpigsthroughadjuvantednanotechnologybasedvaccination AT torrellesjordib innovativeapproachtoinducecrossprotectiveimmunityagainstporcinereproductiveandrespiratorysyndromevirusinthelungsofpigsthroughadjuvantednanotechnologybasedvaccination AT renukaradhyagourapuraj innovativeapproachtoinducecrossprotectiveimmunityagainstporcinereproductiveandrespiratorysyndromevirusinthelungsofpigsthroughadjuvantednanotechnologybasedvaccination |